These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 31884016)
1. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients. Gao L; Hu Y; Shi X; Li X; Zhang D; Ren H Ann Hepatol; 2020; 19(3):329-334. PubMed ID: 31884016 [TBL] [Abstract][Full Text] [Related]
2. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449 [TBL] [Abstract][Full Text] [Related]
3. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study. Zheng Z; Liao W; Liu L; Cai S; Zhu H; Yin S Biomed Pharmacother; 2020 Feb; 122():109698. PubMed ID: 31918272 [TBL] [Abstract][Full Text] [Related]
4. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313 [TBL] [Abstract][Full Text] [Related]
5. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse. Xu WX; Zhang Q; Zhu X; Lin CS; Chen YM; Deng H; Mei YY; Zhao ZX; Xie DY; Gao ZL; Xie C; Peng L Can J Gastroenterol Hepatol; 2018; 2018():1817680. PubMed ID: 29862225 [TBL] [Abstract][Full Text] [Related]
6. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Buster EH; Schalm SW; Janssen HL Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869 [TBL] [Abstract][Full Text] [Related]
7. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA; Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906 [TBL] [Abstract][Full Text] [Related]
8. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470 [TBL] [Abstract][Full Text] [Related]
9. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128 [TBL] [Abstract][Full Text] [Related]
10. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Song JC; Min BY; Kim JW; Kim JY; Kim YM; Shin CM; Lee SH; Hwang JH; Jeong SH; Kim N; Lee DH Korean J Hepatol; 2011 Dec; 17(4):268-73. PubMed ID: 22310791 [TBL] [Abstract][Full Text] [Related]
11. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B. Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J; J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776 [TBL] [Abstract][Full Text] [Related]
12. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593 [TBL] [Abstract][Full Text] [Related]
13. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333 [TBL] [Abstract][Full Text] [Related]
15. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. Nagata N; Kagawa T; Hirose S; Arase Y; Tsuruya K; Anzai K; Shiraishi K; Mine T BMC Gastroenterol; 2016 Mar; 16():38. PubMed ID: 26987437 [TBL] [Abstract][Full Text] [Related]
16. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218 [TBL] [Abstract][Full Text] [Related]
17. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. Lin CC; Bair MJ; Chen CJ; Lee KH; Chen MJ; Liu CY; Chang CW; Hu KC; Liou TC; Lin SC; Wang HY; Chu CH; Shih SC; Wang TE Kaohsiung J Med Sci; 2016 Jan; 32(1):10-5. PubMed ID: 26853169 [TBL] [Abstract][Full Text] [Related]
18. Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B. Li MR; Xi HL; Wang QH; Hou FQ; Huo N; Zhang XX; Li F; Xu XY PLoS One; 2014; 9(6):e98476. PubMed ID: 24905586 [TBL] [Abstract][Full Text] [Related]
19. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. Cai W; Xie Q; An B; Wang H; Zhou X; Zhao G; Guo Q; Gu R; Bao S J Clin Virol; 2010 May; 48(1):22-6. PubMed ID: 20233672 [TBL] [Abstract][Full Text] [Related]
20. When can we stop nucleoside analogues in patients with chronic hepatitis B? Chong CH; Lim SG Liver Int; 2017 Jan; 37 Suppl 1():52-58. PubMed ID: 28052620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]